| Medical Diagnostic Laboratories LLC Patent applications |
| Patent application number | Title | Published |
|---|
| 20120122092 | Compositions and methods for detecting Borrelia afzelii - Disclosed are oligonucleotides useful in methods for determining whether a sample contains | 05-17-2012 |
| 20120088256 | Anaplasma translocated substrate-1 (ATS-1) and sero-detection of anaplasma phagocytophilum - Disclosed is the use of isolated Ats-1 protein in | 04-12-2012 |
| 20120071422 | Therapeutic application of isolated naturally-occuring soluble truncated forms of IL-23 receptor - The present invention relates to an isolated naturally-occurring soluble truncated IL-23Rα protein, which is a translated protein resulting from a mRNA splice variant of IL-23Rα. The soluble IL-23Rα proteins (e.g., Δ9 and Δ8,9) represents a novel soluble IL-23Rα protein, which is lacking a transmembrane domain and has a unique eight (8) amino acids (GLKEGSYC) at its C-terminus end (due to frame-shift). ELISA reveals that Δ9 is present in blood and can serve as a diagnostic tool for auto-immune diseases including Crohn's disease. There is also provided a method of recombinant production for this soluble truncated form of IL-23Rα protein. More importantly, the present invention provides an utility application of the Δ9 and Δ8,9 protein in inhibit IL-23R-mediated cell signaling. More particularly, Δ9 and Δ8,9 blocks STAT3 formation as well as Th17 maturation. There is provided a therapeutic application of Δ9 and Δ8,9 in treating a human patient inflicted with Crohn's disease. | 03-22-2012 |
| 20120071336 | Antibiotic resistance profile for Neisseria gonorrhoeae and use of same in diagnosis and treatment of gonorrhea - The present invention relates to an antibiotic resistance profile for | 03-22-2012 |
| 20120070837 | CIP2A as a biomarker in detection of cervical cancer - The present invention provides methods and compositions for detecting cervical cancer in a human. The present invention provides CIP2A as a biomarker detectable in a biological sample from cervix of an individual, an increased expression of same is an indication of cervical cancer in the individual. CIP2A mRNA or protein can both serve as reliable biomarkers. In one embodiment, the present invention provides a combined use of CIP2A with at least one additional biomarker selected from the group consisting of Ki67, TOP2A, MCM2, MCM5, p14 | 03-22-2012 |
| 20120064509 | Methods and compositions related thereto for detecting and identifying distinct species of nucleic acids from causative agents - Methods are described herein for detecting and identifying distinct species of nucleic acids, in a single container, for example, from a certain genus of infectious agents or otherwise causative agents comprising, for example, providing a forward PCR primer common to a homologous gene region between the distinct species, and providing a reverse PCR primer common to a homologous gene region between the distinct species, to thereby define a PCR target region amongst the species, and providing a first oligonucleotide probe specific to a nucleic acid sequence within the target region that is characteristic of a first species, providing a second oligonucleotide probe specific to a nucleic acid sequence within the target region that is characteristic of a second species, wherein the first and second oligonucleotide probes are each detectably labeled with distinctly different detectable labels, conducting a PCR reaction in the container by means of the primers to amplify the target region amongst the species, and detecting the distinct labels, thereby identifying distinct species of nucleic acids corresponding to distinct species of infectious agents. Methods are preferred, for example, wherein the infectious agent is a member of the Herpesviridae family. | 03-15-2012 |
| 20120058081 | Ex-vivo treatment of peripheral blood leukocytes with IFN-lambda - The present invention provides a method of treating Th2-associated diseases and disorders by modulating the expression or secretion of IL-4, IL-5 and IL-13 using interferon lambda (IFN-λ). For Th2-associated diseases and disorders, cells of a patient having a Th2-associated disease or disorder are treated ex vivo, with IFN-λ and returned to the patient. The present invention also provides a method of ex vivo treatment, in conjunction with co-administration of IFN-λ | 03-08-2012 |
| 20120015362 | Compositions and methods for detecting cryptococcus neoformans - Disclosed are oligonucleotides useful in methods for determining whether a sample contains | 01-19-2012 |
| 20120009572 | Novel single nucleotide polymorphisms and community-associated methicillin-resistant staphylococcus aureus - The present invention is based on the discovery of novel polymorphisms (SNPs) in the penicillin binding protein (pbp3) gene in | 01-12-2012 |
| 20110312876 | Method of determining types I, II, III, IV or V or methicillin-resistant staphylococcus aureus (MRSA) in a biological sample - Disclosed are diagnostic methods for determining a subtype of methicillin-resistant | 12-22-2011 |
| 20110306062 | Babesia microti genomic clones containing novel antigens useful in the diagnosis of babesios - Disclosed are the cloning and expression of novel antigens in | 12-15-2011 |
| 20110268707 | Ex-vivo treatment of peripheral blood leukocytes with IFN-lambda - The present invention provides an ex vivo method of treating plasmacytoid dendritic cells (pDC) in Th2- or Th17-associated diseases by modulating the cytokine expression or secretion using interferon lambda (IFN-λ). For the Th-2 or Th17-associated diseases, pDC cells from a patient having the disease are exposed ex vivo with IFN-λ in an effective amount to inhibit cytokine releases. The IFN-λ exposed pDC are administered back into the patient. The present invention also provides a method of ex vivo IFN-λ treatment of pDC, in conjunction with co-administration of a composition comprising IFN-λ. | 11-03-2011 |
| 20110237643 | Identification of a Novel repressor on IFN-lambda promoter and siRNA against ZEB1 and BLIMP-1 to increase IFN-lambda gene activity - The present invention is directed to the identification of a novel repressor located between ˜1.2 kb to ˜1.6 kb from the translation start site of the IFN-λ1 promoter. The present invention provides a method of using siRNAs against ZEB1 (binds to the repressor region) and BLIMP-1 (binds outside the repressor region) and increases the promoter activity of IFN-λ1 (i.e., increases the production of IFN-λ1 protein). siRNAs against ZEB1 mRNA or BLIMP-1 mRNA increase IFN-λ1 gene activity. There is provided a therapeutic application of siRNAs against ZEB1 and BLIMP-1 mRNAs in treating a mammal (including a human) by increasing the production of IFN-λ1 protein that promotes an anti-viral response as well as treats asthma diseases. | 09-29-2011 |
| 20110143377 | Protein fragments of virB10 and sero-detection of anaplasma phagocytophium - Disclosed are cloning and expression of a plurality of protein fragments of virB10, a Type IV Secretion System (TIVSS) in | 06-16-2011 |
| 20110086346 | Novel haplotype tagging single nucleotide polymorphisms and use of same to predict childhood lymphoblastic leukemia - The present invention is directed to novel haplotype tagging single nucleotide polymorphisms (SNPs) in specific regions outside the HFE gene that serve as a reliable biomarker for a decreased risk for childhood lymphoblastic leukemia (ALL) in a child. There is provided herein methods and reagents for assessing the haplotype tagging SNPs selected from the group consisting of rs807212, rs198853, rs9467664, rs2213284, rs2230655 and rs12346. The method useful in applying these SNPs in predicting a decreased risk of childhood lymphoblastic leukemia (ALL) is also disclosed. | 04-14-2011 |
| 20110076699 | Hemolysin and its protein fragments in sero-detection of anaplasma phagocytophilum - Disclosed is the cloning, expression and purification of a hemolysin protein and its protein fragments in | 03-31-2011 |
| 20110053189 | Type IV secretion system proteins in sero-detection of Anaplasma phagocytophium - Disclosed are two (2) proteins in the Type IV Secretion System (TIVSS) in | 03-03-2011 |
| 20100298155 | Antibodies specific to antigens of bartonella henselae and use of these antigens in immunoassays - Disclosed are antibodies that bind to the antigenic proteins GroES, RpIL, GroEL, SodB, UbiG, the ABC transporter, and an expressed antigenic protein of unknown function (the “BepA” protein) of | 11-25-2010 |
| 20100209936 | Novel recombinant 15-kDa polypeptide and use of same in detecting human infection with Bartonella henselae - Disclosed are the cloning and expression of a novel antigen of | 08-19-2010 |
| 20100092959 | Single nucleotide polymorphisms as genetic markers for childhood leukemia - The present invention is directed to a panel of single nucleotide polymorphisms (SNPs) in specific genes that serve as biomarkers for sex-specific childhood leukemia risk. There is provided herein methods and reagents for assessing the specific SNPs in those genes. The method useful in applying these SNPs in predicting an increased risk or a decreased risk for childhood leukemia for males and females is also disclosed. | 04-15-2010 |
| 20100081135 | Single nucleotide polymorphisms and use of same predicting male- specific prenatal loss - The present invention is directed to a panel of single nucleotide polymorphisms (SNPs) in specific genes that serve as biomarkers for sex-specific prenatal loss of a conceptus or embryo. There is provided herein methods and reagents for assessing the specific SNPs in those genes. The method useful in applying these SNPs in predicting an increased risk of prenatal loss is also disclosed. | 04-01-2010 |
| 20100028884 | Detection of penicillin tolerance in group B streptococcus: single nucleotide polymorphisms in penicillin binding protein 4 - Disclosed are methods of detecting penicillin tolerance in Group B | 02-04-2010 |
| 20090325146 | Method of determining susceptibility of a tumor cell to a chemotherapeutic agent: novel use of herpes - The present invention provides a method of determining if a tumor cell is susceptible to killing by a chemotherapeutic agent, comprising: (a) providing a tumor cell; (b) infecting said tumor cell with a herpes simplex virus or a herpes simplex virus defective in an immediate early gene selected from the group consisting of ICP27, ICP4, and ICP22; and (c) determining the presence of apoptotic killing of said tumor cell, wherein the presence of apoptotic killing is indicative of susceptibility to said chemotherapeutic agent. Chemotherapeutic agent may include doxorubicin, etoposide, paclitaxel, cisplatin, or 5-fluorouracil. The present invention also provides a herpes simplex virus promoter construct having a lacZ gene to assess tumor resistance to chemotherapeutic agents. | 12-31-2009 |
| 20090305274 | Method for determining azole resistance in candida glabrata - There is disclosed a method for determining azole resistance in | 12-10-2009 |
| 20090246767 | Compositions and methods for detecting Cryptococcus neoformans - Disclosed are oligonucleotides useful in methods for determining whether a sample contains | 10-01-2009 |
